Forte Biosciences, Inc. develops cancer-selective gene therapies designed to activate a patient’s immune system to fight cancer. The company is advancing a pipeline of product candidates, including Toca 511 and Toca FC, which are in clinical trials for brain cancer. Forte Biosciences focuses on delivering therapeutic genes into the DNA of cancer cells to enhance the immune response against tumors.
- Website
- www.tocagen.com
- Issuer profile
- All listings